Cancer Discov: Venetoclax and Navitoclax, chemotherapy to treat relapse/resuscable acute lymphoblastic leukemia and lymphocytic lymphoma

The prognosis for patients with relapsed/resoicable acute lymphoblastic leukemia (ALL) is still poor, especially those who receive secondary or subsequent rescue treatment.
reported that the rate of full remission (CR) in recurring/resecurable ALL pediatrics and adult patients receiving secondary rescue therapy was as low as 44% and 18%, respectively.
the prognosis of patients with recurring/recurring precursor B/T cell lymphoma (LL) was also so poor.
, in this case, both recurring/recurring ALL and LL are in urgent need of new treatments.
combined with the selective BCL-2 inhibitor venotclax and a small dose of navitoclax (BCL-XL/BCL-2 inhibitors), both BCL-2 and BCL-XL can be targeted without dose-limiting plateplate reduction associated with a single treatment of nacitoclax.
a new study published in Cancer Discovery, "Venetoclax and Navitoclax in Group with Technology in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic" Lymphoma" is a Phase I dose incremental trial (NCT03181126) in which the safety and initial efficacy of venotclax combined small doses of navitoclax and chemotherapy were evaluated in children and adult patients with relapsed/re treatable ALL or LL.
results showed that a total of 47 patients were treated in the study.
Venotclax is recommended for adult patients with a phase II dose of 50 mg and 25 mg for patients weighing less than 45 kg.
safety findings are delays in hemaglysis recovery.
60 per cent, including patients who had previously received hematocyte transplants or immunotherapy.
13 patients (28%) were transplanted or treated with CAR T cells during the study.
, venotclax combined with navitoclax and chemotherapy for different age groups of therapeutic/recurring ALL and LL patients with good tolerance and good efficacy.